CBD Found to Suppress Cancer-Spreading Gene in Lab and Animal Studies
Researchers at California Pacific Medical Center in San Francisco discovered that cannabidiol (CBD), a non-psychoactive compound found in cannabis, can effectively suppress the ID-1 gene responsible for cancer metastasis. The finding, first published in 2007 and expanded through subsequent research, showed that CBD caused aggressive cancer cells to stop spreading and revert to a more normal state in both laboratory and animal models.
Molecular biologist Pierre Desprez had spent approximately 20 years studying the ID-1 gene, which plays a critical role in enabling cancer cells to migrate throughout the body. Fellow researcher Sean McAllister had been independently investigating the biological effects of CBD. When the two combined their areas of expertise, they found that CBD could essentially deactivate ID-1 in cells that contained high concentrations of the gene.
Results Across Multiple Cancer Types
The initial research focused on breast cancer, but subsequent experiments revealed that CBD’s effects extended to other aggressive cancer types. The researchers reported positive results against brain cancer and prostate cancer — specifically in cases where high levels of ID-1 expression were present. The breadth of the finding suggested that CBD’s mechanism of action was not limited to a single cancer type but rather targeted a common molecular pathway shared by multiple aggressive malignancies.
The team reported no observable toxicity in the animals tested. Desprez noted that CBD was already being used in humans for other medical purposes, including the management of anxiety and nausea, and that its non-psychoactive nature meant it did not produce the intoxicating effects associated with THC.
Route of Administration Matters
Despite the promising findings, the researchers emphasized that the therapeutic application of CBD for cancer would require specific delivery methods. The animal studies used injections, and the team was also evaluating pill-based formulations. Desprez made clear that smoking marijuana would not deliver sufficient concentrations of CBD to produce an anti-cancer effect.
The research team had also begun synthesizing CBD in the laboratory rather than extracting it directly from cannabis plants. This approach was intended to increase the compound’s potency and, as Desprez acknowledged, to avoid potential regulatory complications during the approval process for clinical trials.
Awaiting Human Clinical Trials
At the time the research was publicized, the findings had undergone laboratory testing and animal studies. The team was seeking permission to begin clinical trials in humans. Desprez expressed urgency about moving to the trial phase as quickly as possible, given the potential implications for patients with aggressive, metastatic cancers.
The collaboration between Desprez and McAllister underscored the value of interdisciplinary research. Desprez noted that neither scientist would likely have arrived at the discovery working independently, and that the breakthrough was a direct result of combining their distinct areas of expertise.
